Loading
RT
Repare Therapeutics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 17 Nov 2023.
Repare Therapeutics Inc.: what insiders have been doing
Repare Therapeutics Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). 6 insiders have disclosed 6 filings since 18 October 2025.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Compared with its exchange (5,808 companies, median 19 filings), a count of 6 filings is below the norm. Looking back to 2021, when coverage begins, insiders filed 7 purchases and 54 sales.
Over the last twelve months, not one insider purchase of Repare Therapeutics Inc. stock was filed.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
100
Thresholds
n/a
Buy Volume
€20M
7 ops. · all time
Sell Volume
€27M
54 ops. · all time
Who traded when
BuySaleLloyd Mitchell Segal1 sale
Maria Koehler1 sale
Michael Zinda1 sale
Steve Forte1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
Net income-US$72.9M
Last declaration on 30 January 2026
Declarations100 total
5,309,432 sharesCommon Shares, no par valueSEC:0000921895-26-000173:0
56,786 sharesCommon SharesSEC:0001815428-26-000002:0
31,622 sharesCommon SharesSEC:0002065621-26-000002:0
7,500 sharesCommon SharesSEC:0001723092-26-000002:0
8,000 sharesCommon SharesSEC:0001272181-26-000002:0
4,000 sharesCommon SharesSEC:0001250252-26-000002:0
4,100 shares0Common SharesSEC:0001415889-25-011515:0
3,596 shares@ US$1.141.6% of flowCommon SharesSEC:0001415889-25-008108:0
6,884 shares@ US$1.1450.0% of flowCommon SharesSEC:0001415889-25-008106:0
5,611 shares@ US$1.140.6% of flowCommon SharesSEC:0001415889-25-008107:0
21,179 shares@ US$1.144.7% of flowCommon SharesSEC:0001415889-25-008105:0
14,000 shares0Common SharesSEC:0001415889-25-007238:0
14,000 shares0Common SharesSEC:0001415889-25-007237:0
40,000 shares0Common SharesSEC:0001415889-25-007239:0
500 shares@ US$4.640.9% of flowCommon SharesSEC:0001415889-24-009623:0
450 shares@ US$4.640.2% of flowCommon SharesSEC:0001415889-24-009625:0
2,650 shares@ US$4.622.4% of flowCommon SharesSEC:0001415889-24-009629:0
825 shares@ US$4.6224.5% of flowCommon SharesSEC:0001415889-24-009627:0
2,650 shares@ US$4.792.5% of flowCommon SharesSEC:0001415889-24-009249:0
500 shares@ US$4.781.0% of flowCommon SharesSEC:0001415889-24-009251:0
825 shares@ US$4.7925.4% of flowCommon SharesSEC:0001415889-24-009255:0
450 shares@ US$4.780.2% of flowCommon SharesSEC:0001415889-24-009253:0
14,000 shares0Common SharesSEC:0001415889-24-006590:0
40,000 shares0Common SharesSEC:0001415889-24-006464:0
14,000 shares0Common SharesSEC:0001415889-24-006462:0
25 of 100 declarations
About Repare Therapeutics Inc.
Repare Therapeutics Inc. (ticker: RPTX) is a clinical-stage biotechnology company listed on the NASDAQ market in the United States (United States), focused on precision oncology. The company’s scientific core is a synthetic lethality platform, designed to identify genetic vulnerabilities in cancer cells and translate those insights into targeted therapies. Repare was founded in 2016 and incorporated under the Canada Business Corporations Act on September 6, 2016. Operationally, it is anchored in Montreal, Quebec, with a significant presence in Cambridge, Massachusetts, and it also maintains Repare Therapeutics USA Inc., its U.S. subsidiary. This cross-border setup gives the company access to both Canadian scientific talent and the large U.S. capital and clinical ecosystem.
Repare’s business model is centered on proprietary drug discovery and development, supported by its SNIPRx® platform and a genomics-driven approach to patient selection. Rather than operating as a commercial drug company, Repare is still in the high-risk, high-reward development phase, where the value proposition depends primarily on clinical execution, regulatory progress, and strategic partnering. Its pipeline has historically included both partnered and wholly owned assets, but management has increasingly focused the portfolio on a smaller number of programs with the highest near- to medium-term potential.
Read moreShow less
Key product candidates include lunresertib (RP-6306), a PKMYT1 inhibitor; camonsertib (RP-3500), an ATR inhibitor; RP-1664, a PLK4 inhibitor; and RP-3467, a Polθ ATPase inhibitor. These programs target DNA damage response and cell-cycle biology, areas that remain highly active in oncology research because they may create differentiated opportunities in genomically defined tumors. Repare’s competitive position is therefore that of a science-led precision oncology platform company, competing against other biotech firms developing DNA repair and replication stress therapies. Its edge lies in target selection, translational data, and the ability to generate clinically meaningful signals in biomarker-selected populations.
Recent developments have been strategically important. In 2024 and 2025, the company undertook portfolio reprioritization and cost reductions, concentrating resources on RP-1664 and RP-3467 while seeking partnerships for lunresertib and camonsertib. In parallel, Repare reported ongoing clinical activity and preclinical work across its pipeline. Most notably, the company later announced a definitive agreement to be acquired by XenoTherapeutics, Inc., subject to customary approvals, and separately disclosed an asset sale of RP-3467 to Gilead Sciences for up to $30 million in total consideration. For investors, RPTX remains a NASDAQ-listed United States biotech story defined less by current revenues than by clinical milestones, portfolio monetization, and transaction-driven optionality.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
